^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BAY2701438
i
Other names: BAY2701438, BAY 2701438
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Bayer
Drug class:
HER2 inhibitor
Related drugs:
over2years
A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov)
P1, N=213, Recruiting, Bayer | Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Jul 2025 --> Jul 2026
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression
|
BAY2701439 • BAY2701438
3years
A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov)
P1, N=213, Recruiting, Bayer | Trial completion date: Sep 2026 --> Jul 2027 | Trial primary completion date: Dec 2024 --> Jul 2025
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression
|
BAY2701439 • BAY2701438
over4years
A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov)
P1;Not yet recruiting --> Recruiting
Enrollment open • Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression
|
BAY2701439 • BAY2701438
over4years
A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov)
P1, N=176, Not yet recruiting, Bayer | Initiation date: Mar 2020 --> Sep 2020
Clinical • Trial initiation date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression
|
BAY2701439 • BAY2701438
almost5years
A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov)
P1, N=176, Not yet recruiting, Bayer | Trial completion date: May 2027 --> Sep 2026 | Trial primary completion date: Apr 2025 --> Oct 2024
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression
|
BAY2701439 • BAY2701438
5years
A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov)
P1, N=176, Not yet recruiting, Bayer
Clinical • New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression
|
BAY2701439 • BAY2701438
Share via
